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Abstract
Introduction: Platelet-rich plasma (PRP) is widely used to treat tendon injuries in clinics. These PRP preparations often
contain white blood cells or leukocytes, and the precise cellular effects of leukocyte-rich PRP (L-PRP) on tendons are
not well defined. Therefore, in this study, we determined the effects of L-PRP on tendon stem/progenitor cells (TSCs),
which play a key role in tendon homeostasis and repair.
Methods: TSCs isolated from the patellar tendons of rabbits were treated with L-PRP or P-PRP (pure PRP without
leukocytes) in vitro, followed by measuring cell proliferation, stem cell marker expression, inflammatory gene
expression, and anabolic and catabolic protein expression by using immunostaining, quantitative real-time
polymerase chain reaction, Western blot, and enzyme-linked immunosorbent assay, respectively.
Results: Cell proliferation was induced by both L-PRP and P-PRP in a dose-dependent manner with maximum
proliferation at a 10 % PRP dose. Both PRP treatments also induced differentiation of TSCs into active tenocytes.
Nevertheless, the two types of PRP largely differed in several effects exerted on TSCs. L-PRP induced predominantly
catabolic and inflammatory changes in differentiated tenocytes; its treatment increased the expression of catabolic
marker genes, matrix metalloproteinase-1 (MMP-1), MMP-13, interleukin-1beta (IL-1β), IL-6 and tumor necrosis
factor-alpha (TNF-α), and their respective protein expression and prostaglandin E2 (PGE2) production. In contrast,
P-PRP mainly induced anabolic changes; that is, P-PRP increased the gene expression of anabolic genes, alpha-smooth
muscle actin (α-SMA), collagen types I and III.
Conclusions: These findings indicate that, while both L-PRP and P-PRP appear to be “safe” in inducing TSC
differentiation into active tenocytes, L-PRP may be detrimental to the healing of injured tendons because it
induces catabolic and inflammatory effects on tendon cells and may prolong the effects in healing tendons.
On the other hand, when P-PRP is used to treat acutely injured tendons, it may result in the formation of
excessive scar tissue due to the strong potential of P-PRP to induce inordinate cellular anabolic effects.
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Introduction
Acute and chronic tendon injuries affect millions of
people in both occupational and athletic settings each
year. Healing of acute injuries results in the formation of
scar tissue in tendons, which have inferior mechanical
strength that makes them susceptible to re-injury [1]. On
the other hand, the current treatment of chronic tendon
injury (or tendinopathy) is largely palliative because of the
incomplete understanding of the tendon disorder [2]. In
recent years, a new treatment option involving the injec-
tion or implantation of platelet-rich plasma (PRP) has
been used in orthopaedic surgery and sports medicine to
treat tendon injuries [3–5].
PRP is the plasma fraction derived from a person’s own
blood and contains high concentrations of platelets that
house a sleuth of growth factors such as platelet-derived
growth factor, transforming growth factor-beta, vascular
endothelial growth factor, and hepatocyte growth factor,
which are known to play a critical role in tissue healing
[6, 7]. After a simple centrifugation process, the platelet-
containing PRP is injected into the injured area during the
treatment protocol. PRP has several distinct advantages: it
is autologous and biocompatible, making it inherently
safe; it contains high levels of growth factors that promote
healing of injured tissues; and when injected in vivo, it
forms a fibrin scaffold, which is conducive for cell migra-
tion and new matrix formation [2, 8]. Because of these ad-
vantages, PRP has been used widely to promote bone
formation [9], skin rejuvenation [10], and colon anasto-
mosis [11] among other things. PRP’s safety and ease of
use have also promoted its use among professional ath-
letes to treat soft tissue injuries without hospitalization
[12–14], allowing a quicker return to sports activities.
Particularly, PRP treatment has been successful in healing
injured anterior cruciate ligament, which is known to lack
spontaneous healing ability [15–17].
Despite its widespread use, the efficacy of PRP treatment
on tendon injuries particularly in clinical trials has been
controversial. This is mainly due to inconsistent results
from human clinical trials, and a number of studies have
reported that PRP can effectively treat tendon injuries
[12, 18–22] whereas others have contradicted the posi-
tive outcomes of PRP and noted no improvement in
pain or tendon function after PRP treatment [23–26].
These controversies are likely due to PRP-related fac-
tors such as variations in preparations and dosage, and
patient-related factors such as age, gender, disease history,
and treatment history of patients among others [27]. One
critical component that affects PRP preparations is the
presence or absence of white blood cells (WBCs) or leuko-
cytes (neutrophils, monocytes, macrophages, and lympho-
cytes), which can be beneficial because they stimulate the
immune response against infections [28, 29]; promote
chemotaxis, proliferation, and differentiation of cells; and
induce extracellular matrix production and angiogenesis
[30]. Owing to these properties, PRP-containing leuko-
cytes (L-PRP) are often used to treat traumatic injuries
[31]. However, leukocytes also release inflammatory cyto-
kines—e.g., interleukin-1beta (IL-1β) and tumor necrosis
factor-alpha (TNF-α)—and reactive oxygen species, both
of which can have detrimental effects on the treated tis-
sues [32]. Therefore, it is necessary to define the precise
effects of L-PRP on tendons so that its clinical applications
can be justified or refuted.
In tendons, two cell types exist: tenocytes, which are
the dominant cells, and the tendon stem/progenitor cells
(TSCs), which form a small portion (<5 %) of the total
tendon cells [33]. Similar to other adult stem cells, TSCs
self-renew and can differentiate into tenocytes that are
responsible for the maintenance of the tendons and repair
once injured [34]. Because TSCs play such a critical role
in tendon homeostasis and repair, we designed this study
to determine the effects of L-PRP on TSCs. Specifically,
we tested the hypothesis that L-PRP and P-PRP (pure PRP
without leukocytes) exert differential effects on TSCs,
which may lead to different outcomes of PRP treatment
on tendon injuries.
Methods
Preparation of L-PRP and P-PRP
The protocol for the use of rabbits in this study was
approved by the University of Pittsburgh Institutional
Animal Care and Use Committee. In total, 12 adult New
Zealand White rabbits (6–8 months old, 3.0–4.0 kg) were
used in this study. L-PRP and P-PRP were prepared in
a two-step centrifugation process in accordance with a
previously described protocol [35]. Briefly, whole blood
was centrifuged at 2300 g for 10 s per milliliter of
blood. Then, the top two thirds of the supernatant were
obtained for P-PRP preparation while the lower one
third of the supernatant and buffy coat were collected
for L-PRP preparation. Both supernatants were centri-
fuged separately for a second time at 2200 g for 2 min/
ml and the resulting “pellets” were used as L-PRP and
P-PRP, respectively. The supernatants known as platelet-
poor plasma (PPP) were also collected. The platelet con-
centration in the two preparations was measured by using
an automatic hematology analyzer (CELL-DYN Emerald;
Abbott Laboratories, North Chicago, IL, USA) and ad-
justed to three times higher than the platelet level in
whole blood with PPP. Prior to use in the experiments,
both L-PRP and P-PRP were activated by adding 100
U/ml bovine thrombin (catalog #T4648; Sigma-Aldrich,
St. Louis, MO, USA).
Isolation of rabbit TSCs
TSCs from rabbits were isolated as described previously
[36]. Briefly, rabbits that were used to collect blood as
Zhou et al. Stem Cell Research & Therapy  (2015) 6:173 Page 2 of 13
described above were euthanized, and the patellar ten-
dons from two rabbits were harvested by cutting the
tendons 5 mm from the distal and proximal ends each.
The tendon sheath and surrounding paratenon were
carefully stripped, and the core part of each tendon was
isolated, weighed, and minced into fragments (1 mm ×
1 mm × 1 mm) for cell culture. These tendon fragments
were digested in a solution containing 3 mg/ml collage-
nase type 1 (Worthington Biochemical Corporation,
Lakewood, NJ, USA) and 4 mg/ml dispase (StemCell
Technologies Inc., Vancouver, BC, Canada) in phosphate-
buffered saline (PBS) at 37 °C for 1 h. The final suspension
was centrifuged at 1500 g for 15 min, and the resulting cell
pellet was suspended in growth medium consisting of
Dulbecco’s modified Eagle’s medium (DMEM), 20 % fetal
bovine serum (FBS) (Atlanta Biologicals, Lawrenceville,
GA, USA), and 1 % each of penicillin and streptomycin.
The cell suspension was diluted to 10 cells/μl, and about
2 × 104 cells were seeded into six-well plates and incu-
bated at 37 °C with 5 % O2. After 2 weeks, the TSC col-
onies observed in the wells were detached with trypsin
(0.25 %) and transferred to T25 flasks for further culture
in growth medium. These TSCs at passage 2 were used in
further experiments. Prior to use, the stemness of TSCs
was verified by staining the cells for stem cell markers,
including Oct-4, SSEA-4, and nucleostemin (NS), as
described previously [34].
In vitro culture of TSCs
A transwell system (Transwell, Corning Incorporated,
Corning, NY, USA) was used to culture cells for all the
experiments in this study. This system consists of trans-
well inserts containing a microporous membrane with
0.4-μm pore size that can be inserted into the well of cell
culture plates such that there is free flow of culture
medium between the upper and lower compartments.
First, TSCs in culture medium (DMEM+ 2 % FBS) were
seeded in the lower compartment, the cell culture well.
Activated L-PRP or P-PRP in DMEM+ 2 % FBS was
then added to the upper compartment of the experimen-
tal groups. The control group received DMEM+ 2 %
FBS. The culture medium was collected and changed
every 3 days. The optimal concentration of L-PRP and
P-PRP required for the best growth of TSCs was deter-
mined by cell proliferation assay.
Tendon cell proliferation assay
TSCs were seeded in a 24-transwell system (Transwell,
catalog no. 3413; Corning Incorporated) at a density of
1 × 104 and cultured in growth medium containing L-PRP
or P-PRP at various concentrations: 0 %, 2 %, 5 %, 10 %,
20 % (vol/vol). Cell growth was evaluated on day 3 by
using the Cell Counting Kit-8 (CCK-8) (Sigma-Aldrich,
catalog no. 96992). Fresh culture medium containing 10 %
CCK-8 solution was added to cells and incubated at 37 °C
for 2.5 h. Then, the absorbance was measured by using a
microplate reader (Spectra MAX 190; Molecular Devices,
Sunnyvale, CA, USA) at 450 nm. Each treatment had
three replicates and their absorption was independently
calculated as OD 450nmexperiment – OD 450nmblank. The
average absorption of the three replicates represented cell
proliferation in each treatment group. The PRP concentra-
tion, which induced the highest level of cell proliferation,
was considered the optimal concentration and therefore
was used in the following experiments.
Cell morphology
TSCs were seeded in a 24-transwell system at a density
of 1 × 104 per well and incubated in growth medium
(DMEM+ 2 % FBS) alone (control group) or growth
medium with 10 % L-PRP or 10 % P-PRP (experimental
groups). The cell culture medium was changed every
3 days. After 14 days, cell morphology was first observed
microscopically and images were obtained through a
camera attached to the microscope.
Immunostaining of tendon cells
TSCs cultured as above for 14 days were collected by tryp-
sinization, fixed for 20 min in 4 % paraformaldehyde/PBS,
and washed with 0.1 % Triton-X100/PBS for 5 min. Immu-
nostaining for the stem cell marker NS was performed by
first blocking the fixed cells with 3 % goat serum for 1 h
and then incubating in goat anti-rabbit NS antibody (1:500;
Neuromics, Edina, MN, USA; catalog no. GT15050) for
1 h at room temperature, followed by incubation for the
same time with a Cy3-conjugated donkey anti-goat im-
munoglobulin G (IgG) secondary antibody (Millipore; cata-
log no. AP180S). Nuclei in the cells were counterstained
with Hoechst 33342 (Sigma-Aldrich; catalog no. 33270).
Immunostaining for tenocyte-specific proteins, α-SMA,
and collagen types I and III was performed by blocking
the fixed cells in 2 % mouse serum. Cells were then incu-
bated with mouse monoclonal anti-alpha-smooth muscle
actin (anti-α-SMA) antibody (1:500; Abcam, catalog no.
ab7817, Cambridge, UK), anti-collagen type I antibody
(1:200; Abcam, catalog no. ab6308), or anti-collagen type
III antibody (1:200; catalog no. NBP1-05119; Novus,
Littleton, CO, USA) overnight. After washing in PBS three
times for 5 min each, the cells were further incubated with
Cy3-conjugated goat anti-mouse IgG secondary antibody
(1:500; Millipore; catalog no. AP124X4-K) for 1.5 h. After
a final wash in PBS, the stained cells were examined
through an inverted fluorescence microscope (Nikon
eclipse, TE2000-U; Nikon Inc., Melville, NY, USA) and
images were obtained with a charge-coupled device
camera using the SPOT imaging software (Diagnostic
Instruments, Inc., Sterling Heights, MI, USA).
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Gene Expression Analysis using real-time qRT-PCR
To determine the effects of L-PRP and P-PRP on the
gene expression in tendon cells, we used real-time
quantitative reverse transcription-polymerase chain re-
action (qRT-PCR) to analyze the following genes as
previously described [37, 38]: stem cell-related gene
(Oct-4), tenocyte-related genes (α-SMA and collagen
type I and collagen type III), non-tenocyte related genes
(Sox-9, Runx-2 and PPAR-γ), catabolic genes (MMP-1
and MMP-13), and inflammatory marker genes (IL-1β,
IL-6, and TNF-α). First, TSCs were seeded in a six-
transwell system at a density of 2 × 105 and cultured in
the presence of 10 % L-PRP or 10 % P-PRP. Cells from
each treatment were harvested on day 14 to isolate total
RNA by using the RNeasy Mini Kit with an on-column
DNase I digest (catalog no. 74104; Qiagen, Valencia,
CA, USA). First-strand cDNA was then synthesized
from 1 μg of total RNA by using Super Script II (Invi-
trogen, Grand Island, NY, USA) in the following condi-
tions: 65 °C for 5 min, 4 °C for 1 min, 42 °C for 50 min,
and finally 72 °C for 15 min. Then, qRT-PCR was car-
ried out in a 25-μl reaction volume containing 2 μl of
cDNA (100 ng RNA) as template and gene-specific
primers by using the Qiagen QuantiTect SYBR Green
PCR Kit (Qiagen; catalog no. 204143). All reactions
were performed on a Chromo 4 Detector (MJ Research,
Waltham, MA, USA) by incubating at 94 °C for 5 min,
followed by 40 cycles of a three temperature program
consisting of 1 min at 94 °C, 40 sec at 57 °C, and 40 sec
at 72 °C, followed by a melt-curve analysis. All primers
were synthesized by Invitrogen, and GAPDH (glyceral-
dehyde 3-phosphate dehydrogenase) was used as an in-
ternal control. The sequences of primers used in the
reactions are listed in Table 1 and are based on previ-
ous publications [39–45]. Each reaction had at least
three replicates, and the relative expression of each target
gene was calculated by using the formula 2−ΔΔCT, where
CT is the mean cycle threshold (n = 3) of each cDNA
amplified and ΔΔCT = (CTtarget/CTGAPDH) experiment –
(CTtarget/CTGAPDH) control [46].
Western blot analysis
TSCs were cultured in the presence of 10 % L-PRP or
10 % P-PRP as above. The cell culture medium was
changed every 3 days. After 14 days, they were harvested
by using trypsin and centrifuged to obtain cells from
each group. Total proteins were then isolated by lysing
cells by using a mammalian protein extraction reagent
(M-PER) (Thermo, Waltham, MA, USA, catalog no.
78505) containing 1.5 % protease inhibitors (Sigma-Al-
drich) followed by centrifugation at 14,000 g for 10 min.
The resulting supernatant was stored at 4 °C. Protein
concentration in the supernatant was determined by
using the BCA Protein Assay Kit (Thermo, catalog no.
23225). Equal amounts of total protein from each group
were then separated on 12 % SDS-PAGE gels (Thermo,
catalog no. 25222) at a constant 100 V for 60 min. For
Western blot analysis, proteins were transferred to a
nitrocellulose membrane by using a semi-dry transfer
module (Bio-Rad Laboratories, Hercules, CA, USA) at
200 mA for 90 min. The membrane was blocked in 5 %
dry milk/TBS-Tween 20 for 1 h at room temperature
and then incubated overnight at room temperature with
a mouse monoclonal anti-α-SMA antibody (Abcam,
catalog no. ab7817) at a dilution of 1:1000, anti-collagen
type I antibody (Abcam, catalog no. ab6308) at a dilution
of 1:250, or anti-collagen type III antibody (Novus, catalog
no. NBP1-05119) at a dilution of 1:250. The membranes
were washed in PBS/Tween-20 three times for 10 min
each and further incubated with peroxidase-conjugated
goat anti-mouse antibody (Santa Cruz Biotechnology,
Dallas, TX, USA, catalog no. sc-2005) at a dilution of
1:2500 in 1 % dry milk/PBS for 1 h at room temperature.
Finally, the protein bands were detected by using an ECL
(enhanced chemiluminescence) detection kit (Amersham
Biosciences, Piscataway, NJ, USA), followed by exposing
the membrane to x-ray films for visualization. Mouse anti-
human GAPDH (Chemicon, Temecula, CA, USA) was
used as an internal control to verify the loading of equal
amounts of proteins in each well. After the protein bands
Table 1 Primers used in quantitative reverse transcription-
polymerase chain reaction for gene expression analysis
Gene Primer Sequence Reference
Oct-4 For 5′-CGA GTG AGA GGC AAC TTG G-3′ [42]
Rev 5′-CGG TTA CAG AAC CAC ACA CG-3′
Sox-9 For 5′-TGA ATC TCC TGG ACC CCT TC-3′ [44]
Rev 5′-CCG TTC TTC ACC GAC TTC CT-3′
Runx-2 For 5′-TGA TGA CAC TGC CAC CTG TG-3′ [44]
Rev 5′-ACT CTG GCT TTG GGA AGA GC-3′
PPAR-γ For 5′-TGC AGG AGC AGA GCA AAG AAG-3′ [45]
Rev 5′-GAG GCC AGC ATG GTG TAG ATG-3′
MMP-1 For 5′-ATA CCT GGA AAA CTA CTA CAA TCT G-3′ [39]
Rev 5′-TCT TCA GGG TTT CAG CAT CT-3′
MMP-13 For 5′-TGC CCC TCC TCA ACA GTA AC-3′ [39]
Rev 5′-GAG CCC GCT GCA TTC TTC TT-3′
IL-1β For 5′-GTC GTT GTG GCT CTG GAG AA-3′ [41]
Rev 5′-TGC CAG ACA ACA CCA AGG AT-3′
IL-6 For 5′-CTG GTG GTG GCT ACC GCT TT-3′ [39]
Rev 5′-ATG GTC TCC AGG ATG CTC CG-3′
TNF-α For 5′-CAG CCT CTT CTC TTT CCT GCT-3′ [39]
Rev 5′-CCG ATC ACC CTG AAG TGC-3′
GAPDH For 5′-AAG GCC ATC ACC ATC TTC CA-3′ [39]
Rev 5′-GGA TGC GTT GCT GAC AAT CT-3′
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on Western blots were obtained, semi-quantification was
performed by using ImageJ (National Institutes of Health,
Bethesda, MD, USA).
Quantifying total collagen, MMP-1, and MMP-13
production
TSCs were seeded in a six-transwell system at a density
of 2 × 105 per well and incubated in DMEM+ 2 % FBS
(control group) or DMEM+ 2 % FBS + 10 % L-PRP or
10 % P-PRP (experimental groups). Each group had at
least three replicates. The cell culture medium was
changed every 3 days. After 7 days, the supernatant was
collected from each well, and cells were detached by tryp-
sinization and counted by using an auto cellometer (Cell-
ometer Auto T4; Nexcelom Bioscience LLC, Lawrence,
MA, USA). Total collagen production in each well was
measured (90 % confluent) by using the Sircol collagen
assay kit (Biodye Science, Biocolor Ltd., Carrickfergus,
Northern Ireland, UK). In a separate culture, MMP-1 and
MMP-13 levels in the supernatant were also measured
after 4 days by using enzyme-linked immunosorbent assay
(ELISA) assay kits in accordance with the instructions of
the manufacturer (MMP-1 and MMP-13; Biotang Inc.,
Boston, MA, USA).
Measuring IL-1β, IL-6, and TNF-α
First, TSCs were cultured as above either in growth
medium alone (control) or in growth medium containing
10 % L-PRP or 10 % P-PRP with fresh medium replen-
ished every third day in culture. At least three replicates
were maintained for each group. After 4 days, cells were
collected by using trypsin and centrifuged; the pellet was
used to estimate the cell count by using an auto cell-
ometer (Cellometer Auto T4; Nexcelom Bioscience LLC),
and the supernatant was used to measure IL-1β, IL-6, and
TNF-α levels by using specific ELISA kits in accordance
with the instructions of the manufacturer: IL-1β - RayBio
Rabbit IL-1 beta ELISA Kit (RayBiotech, Norcross, GA,
USA); IL-6 - Rabbit Interleukin 6, IL-6 ELISA Kit (Cosmo
Bio USA, Carlsbad, CA, USA); and TNF-α - Rabbit
Tumor Necrosis Factor alpha ELISA Kit (MyBioSource,
San Diego, CA, USA).
Measuring PGE2 production
TSCs were cultured as above in growth medium contain-
ing 10 % L-PRP or 10 % P-PRP for 4 days with the
medium changed every third day in culture. Three repli-
cates were maintained for each group. The cell count in
the culture flasks was measured by using an auto cell-
ometer (Cellometer Auto T4; Nexcelom Bioscience LLC)
after trypsinization. PGE2 level in the supernatant was
measured by using the PGE2 ELISA assay kit in accord-
ance with the instructions of the manufacturer (Cayman
Chemical, Ann Arbor, MI, USA).
Statistical analysis
Results are presented as the mean ± standard deviation.
Statistical significance of the results from cell proliferation
experiments was analyzed by performing one-way analysis
of variance followed by Fisher’s protected least significant
difference for multiple comparisons. For statistical analysis
of other results, two tailed, paired, or unpaired Student’s
t test was performed wherever applicable. Differences
between two groups (control, L-PRP, or P-PRP) were
considered significant when P values were below 0.05.
Results
Characterization of L-PRP and P-PRP preparations
Platelet concentrations in the L-PRP and P-PRP prepa-
rations were similar with 8.94–9.81 × 105/μl and 8.87–
9.75 × 105/μl, respectively. These platelet concentrations
are about three times higher than the average platelet level
in rabbit whole blood (3.12 × 105/μl). As expected, the two
preparations differed largely in the amounts of WBCs
present in them; WBC concentration in L-PRP prepara-
tions ranged between 7.1 and 10.5 × 103/μl, which is
higher than the mean WBC concentration in whole rabbit
blood 4.87 × 103/μl. However, the WBC concentration in
P-PRP was negligible (<100/μl).
Tendon cell proliferation rate is PRP dose-dependent
When TSCs were cultured in the presence of L-PRP or
P-PRP, they differentiated (see data below), which are
hitherto referred to as tendon cells or tenocytes. In the
presence of L-PRP or P-PRP, tendon cell proliferation
rate increased in a PRP dose-dependent manner (Fig. 1).
Tendon cell proliferation increased by 46 % in the pres-
ence of 2 % P-PRP and more than 50 % at 5 % and 10 %
P-PRP levels each. However, increasing P-PRP dose to
20 % decreased cell proliferation rate 31 % lower than
10 % P-PRP but still 36 % higher than the control cells
without P-PRP (0 %). Similar results were observed in
the presence of L-PRP with a maximum cell prolifera-
tion rate of 61 % observed at 10 % L-PRP level. In
addition, 20 % L-PRP had the lowest cell proliferation
rate (42 %) (Fig. 1). At each concentration, L-PRP treat-
ment induced significantly higher cell proliferation than
P-PRP. Since maximum proliferation rate was induced
by 10 % L-PRP or 10 % P-PRP, this dose was used for
further analyses.
PRP specifically induces tenocyte differentiation of TSCs
in vitro
Microscopic observations of tendon cell morphology in
the controls revealed the presence of cobblestone-shaped
cells, which is typical for TSCs (Fig. 2a). However, treat-
ment of TSCs with 10 % L-PRP or 10 % P-PRP not only
increased the number of cells in culture but also specific-
ally increased the numbers of elongated cells, which is the
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typical shape of tenocytes, the dominant resident cells in
tendons (Fig. 2b, c). In addition, the number of cells was
evidently higher after treatment with L-PRP than with P-
PRP (Fig. 2b, c). Furthermore, immunostaining for the
stem cell marker, NS (pink dots in Fig. 2d), showed a
higher number of NS-positive cells in the control group
versus the L-PRP- or P-PRP-treated groups (Fig. 2d-f).
Besides, analysis of the Oct-4 gene, a TSC marker by qRT-
PCR, revealed a significant reduction in gene expression
after PRP treatment when compared with the control
(Fig. 2g), indicating that PRP decreases the stemness of
TSCs in vitro. However, neither PRP preparations signifi-
cantly increased or decreased the expression of non-
tenocyte-specific genes (Sox-9, Runx-2, and PPAR-γ)
(Fig. 2h) when compared with the control. These data in-
dicate that both L-PRP and P-PRP preparations induce
specific tenocyte differentiation of TSCs in vitro.
Differentiated TSCs (tenocytes) are active
We then determined whether the tenocytes newly formed
by PRP-induced TSC differentiation were active in
terms of collagen production. We first investigated the
expression of the active tenocyte marker protein, α-
SMA, in TSCs cultured in the presence of 10 % L-PRP
or 10 % P-PRP. Immunostaining showed that PRP
treatment increased the amounts of α-SMA when com-
pared with control (Fig. 3a-c) with maximum staining
observed in cells treated with 10 % P-PRP (Fig. 3c).
Western blot analysis also validated these results, re-
vealing that treatment with 10 % P-PRP induced the
maximum levels of α-SMA in cells while the effect of
10 % L-PRP was not as effective as P-PRP (Fig. 3d).
Quantification of the protein bands on Western blots
also confirmed these observations (Fig. 3e).
Furthermore, immunostaining of the tenocyte-related
proteins, collagen types I and III, with specific antibodies
displayed robust staining for both collagen types in the
PRP-treated cells when compared with the control
(Fig. 4a-f ). In addition, staining for collagen type I was
more intense than for collagen type III. These results
were further confirmed by Western blot analysis where
staining intensity of collagen type I after 10 % P-PRP treat-
ment was much higher than treatment with 10 % L-PRP
(Fig. 4g). However, treatment with 10 % L-PRP induced
higher levels of collagen type III expression than 10 %
P-PRP (Fig. 4g). These results were also corroborated
by semi-quantification of the Western blots (Fig. 4h).
Furthermore, quantification of total collagen produc-
tion in all three groups using the Sircol assay displayed
significantly higher amounts of total collagen in the PRP-
treated cells in comparison with the controls (Fig. 5).
However, 10 % P-PRP (12-fold) induced greater amounts
of total collagen production than 10 % L-PRP (nine-fold).
L-PRP induces more extensive catabolic responses in
differentiated tenocytes
We further investigated the effects of L-PRP and P-PRP
on the expression of catabolic genes in the newly differ-
entiated tenocytes. Treatment with 10 % L-PRP signifi-
cantly upregulated the catabolic genes MMP-1 and
MMP-13 compared with the untreated control, which
was used as the reference (Fig. 6a). MMP-1 registered a
4.0-fold increase when compared with the control,
whereas MMP-13 increased by approximately 2.4-fold.
In addition, analysis of MMP production by ELISA was
also in alignment with the gene expression results and
revealed that 10 % L-PRP induced MMP-1 and MMP-
13 levels approximately 15-fold higher than the control
(Fig. 6b). Although 10 % P-PRP also upregulated the
MMPs (MMP-1, 5-fold; MMP-13, 3.5-fold) when com-
pared with the control, the increase was significantly
less than that induced by 10 % L-PRP.
L-PRP induces higher levels of inflammatory responses in
differentiated tenocytes
To investigate the effects of L-PRP and P-PRP on the
inflammatory responses in the newly differentiated teno-
cytes, we first examined the expression levels of the in-
flammatory genes, IL-1β, IL-6, and TNF-α, by qRT-PCR.
The results showed a significant increase in the expression
of all three genes after treatment with 10 % L-PRP: IL-1β
expression increased by 1.7-fold, IL-6 by 0.6-fold, and
TNF-α by approximately 2.4-fold (Fig. 7a). In contrast,
P-PRP did not have any influence on the expression of
Fig. 1 Proliferation of tendon stem/progenitor cells cultured in various
concentrations of L-PRP or P-PRP. Cell proliferation was measured on
day 3 in culture. Cells proliferated in a dose-dependent manner with
10 % L-PRP and 10 % P-PRP inducing the maximum effects. All data
are mean ± standard deviation of three values. One-way analysis of
variance followed by least significant difference was used for statistical
analysis of the data from each group (L-PRP or P-PRP). For comparing
differences between L-PRP and P-PRP, a t test was used to determine
statistical significance. Note that different letters above bars indicate
significant differences (P < 0.05). L-PRP leukocyte-platelet-rich
plasma, P-PRP pure-platelet-rich plasma, PRP platelet-rich plasma
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IL-1β, decreased IL-6 expression by 0.32-fold, and in-
creased the expression of only TNF-α (0.93-fold) when
compared with the control used as the reference
(Fig. 7a). Moreover, the production level of the inflam-
matory cytokine IL-1β in the cell supernatants was con-
sistent with the above gene expression data (Fig. 7b).
Specifically, in the control culture, IL-1β was below
detection level (45 pg/ml); however, treatment with
10 % L-PRP induced IL-1β levels, whereas 10 % P-PRP
had no effect on IL-1β. IL-6 levels increased 12-fold in
the presence of 10 % L-PRP (Fig. 7b). The remaining
protein expression data were not consistent with their
gene expression results; P-PRP increased IL-6 protein
levels 2-fold and decreased TNF-α 0.6-fold; L-PRP did
not change the protein level of TNF-α when compared
with the control (Fig. 7b). Although the exact reasons for
these results are not clear, they could be due to a high
baseline level of TNF-α in the culture media.
Furthermore, we investigated the production of PGE2 by
tenocytes treated with 10 % L-PRP or 10 % P-PRP by
using ELISA kits. The increase in PGE2 levels by L-PRP
(13-fold) was apparent, but P-PRP treatment did not affect
PGE2 levels in the newly differentiated tenocytes (Fig. 8).
Discussion
PRP treatment is widely used to treat tendon injuries in
clinics, although the efficacy of its treatment is a hotly de-
bated topic. The use of PRP is supported by a number of
human clinical trials as well as basic science studies on
animal models and cell cultures [3, 4, 12, 22, 47]. Whereas
Fig. 2 L-PRP and P-PRP induce TSC differentiation into tenocytes. Morphology of TSCs after 14 days in culture (a-c). In the control (a), cells were
cobblestone-shaped, a typical feature of TSCs. But PRP treatment changed cell morphology into more elongated tenocyte-like cells and increased
the cell numbers (b, c). Immunostaining for the stem cell marker nucleostemin (NS) (d). NS staining was positive in the control (d - pink dots) but
negative in the PRP-treated cells (e, f). Quantitative reverse transcription-polymerase chain reaction analysis (g, h). Expression of the stem cell
marker gene, Oct-4, was reduced in PRP-treated cells (g); however, PRP-induced changes on the expression of non-tenocyte genes, Sox-9, Runx-2,
and PPAR-γ, were minimal (h). Gene expression levels were normalized with respect to the expression GAPDH (glyceraldehyde 3-phosphate
dehydrogenase). Asterisks indicate significant differences (P < 0.05) when compared with the control. Statistical analyses were performed by
using t test with a sample size of at least three in each group. All analyses were performed on cells in culture for 14 days. Bars = 100 μm (a-f). L-PRP
leukocyte-platelet-rich plasma, P-PRP pure-platelet-rich plasma, PRP platelet-rich plasma, TSC tendon stem/progenitor cell
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basic science studies have generally confirmed that PRP
promotes the healing of tendon injuries by enhancing
tendon cell proliferation and anabolic activities, clinical
studies have reported variable results in PRP treatment
outcomes. There are many reasons for the conflicting re-
ports [27]. In this study, we examined an important factor
that may contribute to this inconsistency, which is the
variation in PRP formulations that is due to differences in
the preparation protocols with some resulting in L-PRP
containing variable concentrations of leukocytes and some
resulting in P-PRP without leukocytes.
Therefore, in this study, we investigated whether the
presence of leukocytes in PRP affects the proliferation
and differentiation of TSCs isolated from young adult
rabbits. Our findings demonstrated that both L-PRP and
P-PRP preparations induced TSC differentiation into
active tenocytes, which were proliferating in culture in a
PRP-dose-dependent manner (Figs. 1–5). Thus, neither
L-PRP nor P-PRP appears to pose safety concerns, in
terms of producing non-tendinous tissues in the treated
tendons, for their use in clinics to treat tendon injuries.
However, both PRP preparations differed in the following
aspects: L-PRP treatment increased the expression of cata-
bolic genes and proteins (MMP-1, MMP-13, IL-1β, IL-6,
and TNF-α) and the production of PGE2, an inflammatory
mediator in tendon cells that, at high concentrations, im-
pairs tendon cell proliferation and induces non-tenocyte
differentiation [48]. In contrast, P-PRP specifically induced
differentiation of TSCs into active tenocytes, marked by
α-SMA expression, and stimulated cellular production of
collagen types I and III; more importantly, P-PRP affected
PGE2 production minimally. These findings indicate that
L-PRP and P-PRP exert differential effects on TSCs.
Therefore, the type of PRP preparation (L-PRP vs. P-
PRP) is likely a critical factor in assessing the efficacy
of PRP treatment on tendon injuries in clinics because
they produce differential effects on tendon cells, as
demonstrated by this and other studies. In clinics, PRP
is prepared by using commercially available PRP prep-
aration kits. Although most kits yield high platelet
concentrations (as expected), the level of leukocytes in
the PRP preparations may vary, thus likely contributing
Fig. 3 Tenocytes differentiated from L-PRP- or P-PRP-treated tendon stem/progenitor cells are active. Immunostaining for α-SMA (a-c), which is a
marker of active tenocytes. PRP treatment increased the expression of α-SMA (pink/red stain) with higher staining after P-PRP treatment than with
L-PRP. Nuclei are stained blue with Hoechst 33342. Western blot analysis (d). An intensely stained α-SMA protein band after PRP treatment validated
increased α-SMA protein level albeit P-PRP induced more α-SMA production than L-PRP. Semi-quantification of the Western blots by ImageJ (e). At
least three independent experiments were performed for each analysis. A t test was used to perform statistical analysis. Significant differences (P < 0.05)
between each treatment and the control are indicated by asterisks. The pound sign indicates significant differences between L-PRP and P-PRP
treatments. All analyses were performed after 14 days in culture. Bars = 200 μm. α-SMA alpha-smooth muscle actin, L-PRP leukocyte-platelet-rich plasma,
P-PRP pure-platelet-rich plasma
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to variable treatment efficacies. Indeed, using two com-
mercial kits (GPS and ACP) to prepare PRP, a recent study
showed that active forms of MMP-2, -3, and -9 were
present in both preparations that can induce catabolic
effects on treated tissues and, as a result, could impair tis-
sue healing [49].
The results of this study showed that the anabolic effects
of L-PRP differed from P-PRP because L-PRP induced
higher expression of collagen type III than P-PRP but
lower expression of collagen type I than P-PRP. Because
collagen type I is the principal component in tendons and
collagen type III is present only in small amounts in nor-
mal tendons but large amounts in healing tendons with
scars, these results indicate that the use of L-PRP to treat
injured tendons may lead to scar formation in healing
tendons. Moreover, L-PRP induces extensive catabolic re-
sponses in differentiated TSCs (tenocytes), which may
delay the repair of acutely damaged tendon matrix and
new matrix formation, thus slowing the healing of in-
jured tendons. Last, because L-PRP induces inflamma-
tory responses in tenocytes differentiated from TSCs,
its use to treat the already-inflamed tendinopathic tendons
may only exacerbate the tendon disorder by prolonging
the inflammatory phase, thus impairing the healing
process and leading to increased pain in patients. Caution
should therefore be exercised when using PRP. Based on
the data from this study, we suggest the use of P-PRP to
augment the repair of tendinopathic tendons because of
Fig. 4 Active tenocytes differentiated from TSCs after L-PRP or P-PRP treatment express collagen types I and III. Immunostaining for collagen types
I and III (a-f). Both PRP treatments increased the expression of collagen types I and III (pink/red stain), although cells treated with P-PRP stained
more intensely for collagen type I and those treated with L-PRP stained more robustly for collagen type III. Nuclei are stained blue with Hoechst
33342. Western blot analysis (g) on total proteins extracted from cells cultured with L-PRP or P-PRP. Collagen I protein band was robust in the
P-PRP-treated group; collagen III protein band was more abundant in the L-PRP-treated cells. Semi-quantification of the Western blots by ImageJ (h).
Each data point represents at least three independent experiments. Statistical analyses were performed by using t test. Significant differences
(P < 0.05) between each treatment and the control are indicated by asterisks. The pound sign indicates significant differences (P < 0.05) between
L-PRP and P-PRP treatments. Analyses were performed after 14 days in culture. Bars = 200 μm. Col collagen, GAPDH glyceraldehyde 3-phosphate
dehydrogenase, L-PRP leukocyte-platelet-rich plasma, P-PRP pure-platelet-rich plasma, PRP platelet-rich plasma, TSC tendon stem/progenitor cell
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its anabolic properties and low inflammatory effects. On
the other hand, it is plausible that the strong anabolic
effects of P-PRP may cause fibrosis/scar tissue formation
in acutely injured tendons simply because tenocytes differ-
entiated from TSCs after P-PRP treatment produces
too much collagen in the wound areas. In this situation,
L-PRP with a small number of leukocytes may be benefi-
cial because these inflammatory cells can induce catabolic
effects on the treated tendons to balance out the excessive
anabolic effects of P-PRP. Note that use of L-PRP with
high levels of leukocytes may also lead to scar formation
because of its ability to induce higher collagen type III
production. Therefore, we suggest that whether to use L-
PRP or P-PRP depends on the type of tendon injury (acute
vs. chronic) and treatment phase (early- or late-stage heal-
ing) in clinical settings.
Previous studies have not specifically investigated the
differential effects of L-PRP and P-PRP on TSCs. How-
ever, in an earlier study, we investigated the effects of
PRCR (platelet-rich clot releasate) on TSCs. PRCR is com-
parable to P-PRP in this study except that it was obtained
by activating platelets with calcium chloride instead of
thrombin used in this study. We found that PRCR also
promoted TSC differentiation into active tenocytes and
their proliferation rate and collagen production in vitro
[37]. Using an in vivo animal model, we further showed
that PRP, or specifically PRCR in fibrin gel, reduced ten-
don inflammation [37]. Other studies have reported the
effects of PRP on cell types other than tendon cells. Using
human dermal fibroblasts (HDFs), for example, one study
showed that the treatment of HDFs with 5 % L-PRP sig-
nificantly increased cell proliferation and the expression of
collagen type I and MMP-1 proteins [10]. Similarly, L-PRP
treatment of human chondrocytes from osteoarthritic
cartilage induced catabolic mRNA, particularly IL-1β and
IL-6, whereas P-PRP stimulated chondrocyte anabolism
by increasing the expression of collagen type II and aggre-
can transcripts in chondrocytes [50]. These findings are
consistent with our study on TSCs. Conversely, tendon
injuries treated with both PRP and TSCs together have
been shown to promote tendon healing better than each
component alone [5, 51].
In this study, we found that both L-PRP and P-PRP
had a dose-dependent effect on the proliferation of teno-
cytes differentiated from TSCs and that the optimal ef-
fect was achieved at 10 % L/P-PRP concentration. This
Fig. 5 Tenocytes differentiated from L-PRP- or P-PRP-treated tendon
stem/progenitor cells release abundant collagen into the culture
media after 7 days. Quantification of total collagen was done by
using the Sircol assay. As shown, both PRP preparations significantly
stimulated the production of total collagen in these cells. The collagen
production was normalized to the respective cell number in each
group. The results are expressed as the mean ± standard deviation
of three independent values in each group. A t test was used for
statistical analysis. Asterisks indicate significant differences (P < 0.05)
when compared with the control, and pound represents significant
difference (P < 0.05) between L-PRP and P-PRP treatment. L-PRP
leukocyte-platelet-rich plasma, P-PRP pure-platelet-rich plasma, PRP
platelet-rich plasma
Fig. 6 L-PRP induces greater catabolic responses than P-PRP. Gene
expression analysis of the catabolic markers, MMP-1 and MMP-13, by
quantitative reverse transcription-polymerase chain reaction (a). Unlike
P-PRP, L-PRP significantly induced the expression of both catabolic
genes. The control group was used as the reference. Gene expression
levels were normalized to the expression of GAPDH (glyceraldehyde
3-phosphate dehydrogenase). Data are represented as mean ± SD
of three independent values. MMP production was also measured
by using enzyme-linked immunosorbent assay (b). The production
was normalized to respective cell number in each group. Asterisks
represent significant differences when compared with the respective
control, and the pound symbols indicate significant differences
between L-PRP and P-PRP (P < 0.05). Note that the data for each
group were calculated from three independent values. Data are
expressed as the mean ± SD. A t test was used for statistical analysis.
L-PRP leukocyte-platelet-rich plasma, MMP matrix metalloproteinase,
P-PRP pure-platelet-rich plasma, SD standard deviation
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dose-dependent effect is likely due to the increasing
concentration of platelets in L-PRP and P-PRP. Similar
observations were made by others where 10 % PRP in-
duced the maximum proliferation of mesenchymal stem
cells and a further increase suppressed cell proliferation
[52, 53]. More importantly, a recent evaluation of various
leukocyte-reduced PRP (lrPRP) concentrations on equine
superficial digital flexor tendon illustrated that the
beneficial effects of lrPRP plateaued at a certain platelet
concentration. A further increase resulted in a significant
reduction in collagen types I and III proteins, indicating
that to promote tendon healing, decreasing the levels of
leukocytes in PRP may be more critical than increasing
platelet concentration [54].
Although L-PRP promoted the expression of catabolic
genes in tenocytes differentiated from TSCs, it increased
cell proliferation. This result is consistent with some
previous studies, which reported the positive effects of
leukocytes on cell proliferation [55, 56]. However, the
increase in cell proliferation rate alone cannot be used
to evaluate the effects of L-PRP on cells, because L-PRP
is known mostly for its catabolic effects on cells and
tissues; for example, L-PRP induced the highest levels of
IL-1β and TNF-α in equine ficialis tendon explants [32]
and increased the levels of IL-1β and IL-6 in human
chondrocytes [50]. These results are consistent with
findings of this study indicating that L-PRP induces
more catabolic effects on tendon cells, which could lead
to detrimental effects on injured tendons, such as im-
paired healing.
Similar to our findings, the differential effects of L-PRP
and P-PRP were recently demonstrated on human chon-
drocytes in vitro where L-PRP induced catabolic effects
and P-PRP promoted anabolic effects [50]. In both studies,
IL-1β and IL-6 were upregulated by L-PRP but the effects
of L-PRP on TNF-α differed; it was reported that higher
TNF-α mRNA levels were observed after treatment with
P-PRP when compared to treatment with L-PRP [50].
In this study, we found an opposite trend with L-PRP in-
ducing higher amounts of TNF-α mRNA and protein than
P-PRP. It is yet to be determined whether L-PRP could
Fig. 7 L-PRP produces greater inflammatory responses than P-PRP.
Quantification of inflammatory marker gene expression was performed
by using quantitative reverse transcription-polymerase chain reaction
(a). Gene expression of IL-1β, IL-6, and TNF-α were upregulated by
L-PRP. But P-PRP upregulated only TNF-α, downregulated IL-6, and
did not have a significant effect on IL-1β gene expression (a). The
control group was used as the reference (1-fold). Data are represented
as mean ± SD of three independent values. Additionally, the levels
of IL-1β, IL-6, and TNF-α were measured by using enzyme-linked
immunosorbent assay (b). The concentration of each cytokine in
each group was normalized to its cell number. L-PRP significantly
increased IL-1β and IL-6 protein levels but did not have a significant
effect on TNF-α production. P-PRP did not affect IL-1β, increased IL-6,
and decreased TNF-α protein levels in tenocytes differentiated
from tendon stem/progenitor cells. Asterisks indicate significant
differences between each PRP treatment and the respective control
group (P < 0.05). Pound symbols represent significant differences
between L-PRP- and P-PRP-treated groups (P < 0.05). Note that, for
each group, three independent values were measured from three
experiments, and the results are expressed as the mean ± SD. A t test
was used for statistical analysis. IL interleukin, L-PRP leukocyte-platelet-rich
plasma, P-PRP pure-platelet-rich plasma, SD standard deviation, TNF-α
tumor necrosis factor-alpha
Fig. 8 L-PRP enhances PGE2 production. Enzyme-linked immunosorbent
assay results of PGE2 production by tenocytes after 4 days in culture.
L-PRP induced higher production of PGE2 when compared with P-PRP.
The PGE2 measurements in the three groups (control, L-PRP, and
P-PRP) were normalized to respective cell numbers. Asterisk indicates
comparison between each treatment and the respective control
(P < 0.05). Pound sign indicates comparison between L-PRP and
P-PRP (P < 0.05). Note that, for each group, three independent
values were obtained, and the results are expressed as mean ±
standard deviation. A t test was used for statistical analysis. L-PRP
leukocyte-platelet-rich plasma, PGE2 prostaglandin E2, P-PRP
pure-platelet-rich plasma
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also differently influence various cell types (human chon-
drocytes vs. rabbit TSCs). A striking difference we noticed
between the two studies is that, in the previous study, the
platelet concentration in L-PRP was three times higher
than in P-PRP [50], which makes it difficult to determine
whether the adverse effects of L-PRP was due to the
presence of leukocytes or high platelet concentration.
In our study, the platelet concentration in P-PRP and
L-PRP was comparable, allowing a direct comparison
between the two types of PRP preparations. Our finding is
also supported by McCarrel et al. [32], who reported that
TNF-α gene expression levels were the highest when
equine superficialis explants were treated with L-PRP in
comparison with standard PRP (equivalent to P-PRP in
this study) or PRP with highly concentrated platelets.
Here, platelet concentrations in L-PRP and standard PRP
were similar, supporting the hypothesis that the adverse
effects of leukocytes in PRP on cells may be more than the
deleterious effects of high platelet concentrations on cells.
Conclusions
This study has revealed that both L-PRP and P-PRP in-
duce the differentiation of TSCs into active tenocytes
and increase their proliferation. However, L-PRP in-
duced catabolic and inflammatory responses in differ-
entiated tenocytes, whereas P-PRP mostly augmented
anabolic responses. Therefore, we suggest that, because
of its catabolic and inflammatory action, L-PRP should
not be used in the treatment of chronic tendon injuries
when chronic inflammation and degeneration are in-
volved. Application of L-PRP in such conditions could
only worsen tendon inflammation and degeneration,
thus delaying healing of such tendon injuries. On the
other hand, P-PRP may not be used to treat acutely in-
jured tendons in young adults, because of its potential
to induce the formation of excessive scar tissue due to
its potent anabolic action. Therefore, the choice of PRP
for a treatment should be determined by whether a ten-
don injury is acute or chronic and the treatment phase;
L-PRP could benefit early-phase healing because of its
ability to fight off infections, whereas P-PRP could be
used for late-stage healing because of its anabolic ef-
fects, enabling it to augment and accelerate tendon
healing. On the other hand, the proportion of leukocytes
in PRP should be adjusted on the basis of the tendon
condition. These insights explain, in part, the variable out-
comes of PRP treatments in clinical trials and will improve
future PRP treatments for tendon injuries.
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